ProQR (PRQR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ProQR Therapeutics has appointed Dr. Peter Beal as Chief ADAR Scientist, enhancing their capabilities in RNA editing technology. Dr. Beal, a renowned expert in ADAR biology, will play a pivotal role in optimizing ProQR’s Axiomer RNA editing platform, aimed at developing treatments for genetic diseases. This strategic addition is expected to strengthen ProQR’s position in the cutting-edge field of RNA-based therapies.
For further insights into PRQR stock, check out TipRanks’ Stock Analysis page.
